KR890011594A - 4-아로일이미다졸-2-온의 제약 조성물 - Google Patents

4-아로일이미다졸-2-온의 제약 조성물 Download PDF

Info

Publication number
KR890011594A
KR890011594A KR1019890000960A KR890000960A KR890011594A KR 890011594 A KR890011594 A KR 890011594A KR 1019890000960 A KR1019890000960 A KR 1019890000960A KR 890000960 A KR890000960 A KR 890000960A KR 890011594 A KR890011594 A KR 890011594A
Authority
KR
South Korea
Prior art keywords
composition
methylthio
dihydro
benzoyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019890000960A
Other languages
English (en)
Korean (ko)
Inventor
도메트 잭
더블유. 다니엘슨 더글라스
Original Assignee
개리 디. 스트리트
머렐 다우 파마슈티칼스 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 개리 디. 스트리트, 머렐 다우 파마슈티칼스 인크 filed Critical 개리 디. 스트리트
Publication of KR890011594A publication Critical patent/KR890011594A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019890000960A 1988-01-29 1989-01-28 4-아로일이미다졸-2-온의 제약 조성물 Ceased KR890011594A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14980388A 1988-01-29 1988-01-29
US149.803 1988-01-29

Publications (1)

Publication Number Publication Date
KR890011594A true KR890011594A (ko) 1989-08-21

Family

ID=22531858

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890000960A Ceased KR890011594A (ko) 1988-01-29 1989-01-28 4-아로일이미다졸-2-온의 제약 조성물

Country Status (17)

Country Link
EP (1) EP0326103B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH01226817A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR890011594A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1035242A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR241632A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE78161T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU611757B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE68902056T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK169566B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2051898T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3005792T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT49282A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE62426B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL89049A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ227700A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT89561B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA89552B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0448091T3 (da) * 1990-03-23 1999-05-03 Yoshitomi Pharmaceutical Farmaceutisk præparat indeholdende et i ringe grad vandopløseligt medikament
AU2004299058A1 (en) * 2003-12-12 2005-06-30 Aventis Pharmaceutical, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
CA2572179A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
EP2581082B1 (de) 2011-10-10 2015-12-30 Carinopharm GmbH Pharmazeutische Zusammensetzung zur Behandlung von Status asthmaticus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) * 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
EP0031603A1 (en) * 1979-12-31 1981-07-08 American Cyanamid Company Pharmaceutical composition of matter
OA06863A (fr) * 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs

Also Published As

Publication number Publication date
HUT49282A (en) 1989-09-28
AU2876889A (en) 1989-08-03
IL89049A0 (en) 1989-08-15
CN1035242A (zh) 1989-09-06
ZA89552B (en) 1989-10-25
PT89561B (pt) 1994-01-31
DK169566B1 (da) 1994-12-05
AU611757B2 (en) 1991-06-20
NZ227700A (en) 1990-09-26
ES2051898T3 (es) 1994-07-01
IE890275L (en) 1989-07-29
EP0326103A1 (en) 1989-08-02
PT89561A (pt) 1989-10-04
ATE78161T1 (de) 1992-08-15
DK37589D0 (da) 1989-01-27
JPH01226817A (ja) 1989-09-11
DE68902056D1 (de) 1992-08-20
EP0326103B1 (en) 1992-07-15
IE62426B1 (en) 1995-02-08
DK37589A (da) 1989-07-30
AR241632A1 (es) 1992-10-30
DE68902056T2 (de) 1992-12-03
GR3005792T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-06-07

Similar Documents

Publication Publication Date Title
KR960000219A (ko) 당뇨병 합병증 치료용 조성물
RS50025B (sr) Farmaceutski preparati koji mogu da budu gelirani
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
ES2002750A6 (es) Procedimiento de obtencion de composiciones en emulsion para la administracion parenteral ynu oral de farmacos hidrofobos ionizables, escasamente hidrosolubles.
CA2294031A1 (en) Self-emulsifying formulation for lipophilic compounds
FR2635265B1 (fr) Composition pharmaceutique intraveineuse comprenant de la cyclosporine en tant que principe actif et procede pour sa preparation
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
KR900012612A (ko) 제약 조성물
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
KR830005854A (ko) 알카리성 진통제 캡슐의 제조방법
KR900004352A (ko) 뇌졸중 치료용 의약
KR910007509A (ko) 친유성 약제용 주사 조성물
DK0693926T3 (da) Ny farmaceutisk sammensætning til fremstilling af et stabilt pulver indeholdende en kombination af acetylsalicylsyre og metoclopramid som aktiv bestanddel.
KR910005876A (ko) 모세혈관 취약증의 치료를 위한 극소용 약학적 조성물
KR890011594A (ko) 4-아로일이미다졸-2-온의 제약 조성물
KR890006236A (ko) 피페리디노 알칸올-충혈제거제 조합을 위한 약제학적 조성물
Kihara et al. AT-1015, a novel serotonin (5-HT) 2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats
JPS5350141A (en) Stabilization of prostaglandin and prostaglandin analogues
FR2719771B1 (fr) Compositions pharmaceutiques contenant du gemfibrozil.
KR910004181A (ko) 생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태
KR920000316A (ko) 젬피브로질 제제
KR920700641A (ko) 클로르메티아졸의 신경 변성 예방 및(또는) 치료용 용도
KR900013959A (ko) γ-카르블린 또는 그들의 제약학적으로 허용 가능한 산부가염 및/또는 수화물, 및 그들로 구성되는 제약학적 조성물
KR920019344A (ko) α-리놀렌산을 이용한 간장질환의 예방 및 치료 조성물
KR950016756A (ko) 피로회복제 조성물

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890128

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19931216

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19890128

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970507

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19970826

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19970507

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I